Metamizol for the Treatment of Neoplastic Chronic Pain

Phase 4TerminatedNCT02181920

Boehringer Ingelheim6 enrolled

Overview

Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Pain

Interventions

MetamizoleDRUG

DiclofenacDRUG

Diclofenac placeboDRUG

Metamizole placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized patients with neoplastic chronic pain requiring morphine treatment Exclusion Criteria: * Karnofsky index less than 30%

Outcomes

Primary Outcomes

Change in morphine requirement

Time frame: Baseline, 9 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.